A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

Several companies across various sectors on the Wall Street have seen some Seeking Alpha analyst activity, including both ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients ...

Mounjaro is one of the bestselling weight loss drugs. See what your options are if you want to invest in Mounjaro stock.

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...